These stocks, sorted into four cohorts based on year-end 2021 valuations, are being tracked by Evaluate Vantage over the year.Īn analysis looking at the combined performance of these four groups was published earlier this week ( The gloom deepens for biopharma stocks, October 10, 2022).
This analysis was constructed from the almost 700 listed biopharma companies covered by Evaluate Pharma, and that were worth at least $250m at the start of 2022. And on the up are developers that have delivered pipeline progress, like Lilly, Daiichi and Sarepta. The unwinding of the Covid trade is readily apparent in Evaluate Vantage’s latest quarterly look at the sector’s biggest winners and losers. With big pharma now feeling the pressure alongside small and mid-cap groups, safe havens are proving hard to find.
Three quarters of the trading year are done, and many biopharma stocks are in a perilous state.
